Aktis Oncology Inc (AKTS) Price Prediction & ForecastAKTSAktis Oncology Inc

Alphio's AKTS stock price prediction model matches the current Aktis Oncology Inc tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $16.90 (+0.30%). The 1-week path is $16.79 (-0.35%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

Aktis Oncology (AKTS) appears to be a good buy right now, especially given its current price of $15.73, which is significantly below the analyst price targets of $40 and $35. The company has a strong gross margin of 100%, indicating effective cost management in its operations. However, it is important to note the risk of its net income, which has been negative, with a reported net income of -24,144,000 USD in Q2 2026. This financial performance, combined with the potential upside indicated by the analyst ratings, supports a buy recommendation.

Aktis Oncology Inc (AKTS) last closed at $16.8500004, gaining +0.18%. These facts feed the 1-day and 1-week AKTS price prediction above.